Nektar Therapeutics Rises on Positive Dermatitis Drug Data

Dow Jones

Feb 10

By Adriano Marchese

Nektar Therapeutics shares rose in premarket trading Tuesday after the company said it received positive data from its dermatitis drug study.

Shares traded 13% higher ahead of the morning bell at $42.04.

The clinical-stage biotechnology company reported positive results from the 36-week blinded maintenance period of the 52-week Rezolve-AD phase 2b study of the new drug rezpegaldesleukin, a novel regulatory T-cell biologic, which aims to treat moderate-to-severe atopic dermatitis.

Atopic dermatitis causes skin irritations in the form of itchiness, inflammation and scaliness due to a combination of an overactive immune system, a weakened skin barrier and the environment.

The company noted that about 71% and 83% of patients kept their level of improvement while 85% and 63% showed signs of skin that cleared or almost cleared, on monthly and quarterly doses, respectively.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

February 10, 2026 08:01 ET (13:01 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610872628"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610872628\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610872628?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610872628","market":"other","top_or_hot":-1,"title":"Nektar Therapeutics Rises on Positive Dermatitis Drug Data","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares rose in premarket trading Tuesday after the company said it received positive data from its dermatitis drug study. \n</p>\n<p>\n  Shares traded 13% higher ahead of the morning bell at $42.04. \n</p>\n<p>\n  The clinical-stage biotechnology company reported positive results from the 36-week blinded maintenance period of the 52-week Rezolve-AD phase 2b study of the new drug rezpegaldesleukin, a novel regulatory T-cell biologic, which aims to treat moderate-to-severe atopic dermatitis. \n</p>\n<p>\n  Atopic dermatitis causes skin irritations in the form of itchiness, inflammation and scaliness due to a combination of an overactive immune system, a weakened skin barrier and the environment. \n</p>\n<p>\n  The company noted that about 71% and 83% of patients kept their level of improvement while 85% and 63% showed signs of skin that cleared or almost cleared, on monthly and quarterly doses, respectively. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 10, 2026 08:01 ET (13:01 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Therapeutics Rises on Positive Dermatitis Drug Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Therapeutics Rises on Positive Dermatitis Drug Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-10 21:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares rose in premarket trading Tuesday after the company said it received positive data from its dermatitis drug study. \n</p>\n<p>\n  Shares traded 13% higher ahead of the morning bell at $42.04. \n</p>\n<p>\n  The clinical-stage biotechnology company reported positive results from the 36-week blinded maintenance period of the 52-week Rezolve-AD phase 2b study of the new drug rezpegaldesleukin, a novel regulatory T-cell biologic, which aims to treat moderate-to-severe atopic dermatitis. \n</p>\n<p>\n  Atopic dermatitis causes skin irritations in the form of itchiness, inflammation and scaliness due to a combination of an overactive immune system, a weakened skin barrier and the environment. \n</p>\n<p>\n  The company noted that about 71% and 83% of patients kept their level of improvement while 85% and 63% showed signs of skin that cleared or almost cleared, on monthly and quarterly doses, respectively. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 10, 2026 08:01 ET (13:01 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2610872628","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610872628","pubTimestamp":1770728460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Nektar Therapeutics shares rose in premarket trading Tuesday after the company said it received positive data from its dermatitis drug study.Shares traded 13% higher ahead of the morning bell at $42.04.The clinical-stage biotechnology company reported positive results from the 36-week blinded maintenance period of the 52-week Rezolve-AD phase 2b study of the new drug rezpegaldesleukin, a novel regulatory T-cell biologic, which aims to treat moderate-to-severe atopic dermatitis.Atopic dermatitis causes skin irritations in the form of itchiness, inflammation and scaliness due to a combination of an overactive immune system, a weakened skin barrier and the environment.The company noted that about 71% and 83% of patients kept their level of improvement while 85% and 63% showed signs of skin that cleared or almost cleared, on monthly and quarterly doses, respectively.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NKTR":"内克塔治疗"},"translate_title":"Nektar Therapeutics因皮炎药物数据积极而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":1.5},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Nektar Therapeutics shares rose in premarket trading Tuesday after the company said it received positive data from its dermatitis drug study. \n\n\n  Shares traded 13% higher ahead of the morning bell at $42.04. \n\n\n  The clinical-stage biotechnology company reported positive results from the 36-week blinded maintenance period of the 52-week Rezolve-AD phase 2b study of the new drug rezpegaldesleukin, a novel regulatory T-cell biologic, which aims to treat moderate-to-severe atopic dermatitis. \n\n\n  Atopic dermatitis causes skin irritations in the form of itchiness, inflammation and scaliness due to a combination of an overactive immune system, a weakened skin barrier and the environment. \n\n\n  The company noted that about 71% and 83% of patients kept their level of improvement while 85% and 63% showed signs of skin that cleared or almost cleared, on monthly and quarterly doses, respectively. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2026 08:01 ET (13:01 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}